Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Cash & Equivalents (2017 - 2026)

Inspire Medical Systems' Cash & Equivalents history spans 10 years, with the latest figure at $98.9 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 83.61% to $98.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $98.9 million, a 83.61% increase, with the full-year FY2025 number at $104.8 million, down 30.19% from a year prior.
  • Cash & Equivalents hit $98.9 million in Q1 2026 for Inspire Medical Systems, down from $104.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for INSP hit a ceiling of $467.1 million in Q2 2023 and a floor of $53.9 million in Q1 2025.
  • Historically, Cash & Equivalents has averaged $224.3 million across 5 years, with a median of $185.5 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: soared 150.34% in 2023 and later tumbled 69.28% in 2025.
  • Tracing INSP's Cash & Equivalents over 5 years: stood at $441.6 million in 2022, then plummeted by 57.98% to $185.5 million in 2023, then dropped by 19.07% to $150.2 million in 2024, then tumbled by 30.19% to $104.8 million in 2025, then fell by 5.61% to $98.9 million in 2026.
  • Business Quant data shows Cash & Equivalents for INSP at $98.9 million in Q1 2026, $104.8 million in Q4 2025, and $112.8 million in Q3 2025.